Xponance Inc. Acquires 34,344 Shares of Pfizer Inc. (NYSE:PFE)

Xponance Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 851,248 shares of the biopharmaceutical company's stock after acquiring an additional 34,344 shares during the quarter. Xponance Inc.'s holdings in Pfizer were worth $22,584,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Generali Asset Management SPA SGR bought a new position in shares of Pfizer during the fourth quarter valued at $11,538,000. Horizon Investments LLC increased its holdings in shares of Pfizer by 1.6% during the fourth quarter. Horizon Investments LLC now owns 82,602 shares of the biopharmaceutical company's stock worth $2,156,000 after buying an additional 1,271 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Pfizer by 8.6% in the fourth quarter. Advisors Asset Management Inc. now owns 748,468 shares of the biopharmaceutical company's stock valued at $19,857,000 after acquiring an additional 59,283 shares during the last quarter. Brooktree Capital Management grew its position in Pfizer by 1.2% during the 4th quarter. Brooktree Capital Management now owns 115,383 shares of the biopharmaceutical company's stock worth $3,061,000 after acquiring an additional 1,389 shares during the last quarter. Finally, PDS Planning Inc increased its holdings in Pfizer by 4.0% during the 4th quarter. PDS Planning Inc now owns 32,708 shares of the biopharmaceutical company's stock valued at $868,000 after purchasing an additional 1,262 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.06% of the company's stock.

Pfizer Trading Down 0.5 %

NYSE PFE traded down $0.14 on Wednesday, reaching $26.18. The company had a trading volume of 27,238,712 shares, compared to its average volume of 35,768,108. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock's 50 day moving average is $26.21 and its 200-day moving average is $27.09. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $148.34 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the prior year, the business posted $0.10 EPS. Pfizer's revenue was up 24.7% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Finally, Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.